AstraZeneca PLC (AZN) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $184.64, but acceptable to hold if already in. Reason: Thin upside margin: 5.8%.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex,... Read more
Hold if already holding. Not a fresh buy at $184.64, but acceptable to hold if already in. Reason: Thin upside margin: 5.8%. Chart setup: RSI 49 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 69d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and news legal. Suitability: moderate.
Recent Developments — AstraZeneca PLC
Latest news
- AstraZeneca (AZN) Stock Slips Despite Q1 Revenue and EPS Beat – Here’s Why - MEXC — MEXC positive
- AstraZeneca: Q1 Earnings Analysis: An Excellent Long-Term Buy And Hold (NYSE:AZN) - Seeking Alpha — Seeking Alpha positive
- What's Going On With AstraZeneca Stock Wednesday? - AstraZeneca (NYSE:AZN) - Benzinga — Benzinga neutral
- AstraZeneca PLC 2026 Q1 - Results - Earnings Call Presentation (NYSE:AZN) 2026-04-29 - Seeking Alpha — Seeking Alpha neutral
- AZN Q1 Earnings and Sales Beat, Key Drugs Offset Generic Pressure - TradingView — TradingView positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $184.64, but acceptable to hold if already in. Reason: Thin upside margin: 5.8%. Chart setup: RSI 49 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $195.31 (+5.8%), stop $177.54 (−4.0%), A.R:R 1.2:1. Score 5.9/10, moderate confidence.
Take-profit target: $195.31 (+5.8% upside). Target $195.31 (+5.8%), stop $177.54 (−4.0%), A.R:R 1.2:1. Stop-loss: $177.54.
Thin upside margin: 5.8%.
AstraZeneca PLC trades at a P/E of 27.7 (forward 31.2). TrendMatrix value score: 4.9/10. Verdict: Hold.
36 analysts cover AZN with a consensus score of 4.1/5. Average price target: $224.
What does AstraZeneca PLC do?AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization...
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.